Elán is a major drugs firm based in Athlone, County Westmeath, Ireland. In the late 1990's its value as a PLC on the ISEQ Stock Exchange reached over €20bn. It was one of Ireland's major business success stories. However in the early years of 2000's an accounting scandal and investor reactions to the globely slump, caused a major devalutation resulting in a share price slump of over 90%. Since then the company has regained its growth path under the rain of a new American CEO Martin Kelly. Today Elán still employs over 2,000 people in Ireland. It is listed on the New York Stock Exchange as ELN, the Dublin Stock Exchange as ELN.I, and the London Stock Exchange as ELN.L.
Elán currently is marketing four drugs in the USA: AZACTAM™, FROVA™, MAXIPIME™, MYOBLOC™,
Elán is focusing its research at the moment on a ground breaking drug for Alzheimer's disease.